Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.

Di Veroli GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR.

Am J Physiol Heart Circ Physiol. 2013 Jan 1;304(1):H104-17. doi: 10.1152/ajpheart.00511.2012. Epub 2012 Oct 26.

2.

Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.

Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC.

J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):178-91. doi: 10.1016/j.vascn.2010.02.007. Epub 2010 Feb 19.

PMID:
20172036
3.

Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.

Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D.

Cardiovasc Res. 2011 Jul 1;91(1):53-61. doi: 10.1093/cvr/cvr044. Epub 2011 Feb 7.

4.

Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.

Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, Thong B.

J Cardiovasc Electrophysiol. 2004 Nov;15(11):1302-9.

PMID:
15574182
5.

Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.

Marostica E, Van Ammel K, Teisman A, Boussery K, Van Bocxlaer J, De Ridder F, Gallacher D, Vermeulen A.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):659-79. doi: 10.1007/s10928-015-9434-0. Epub 2015 Aug 11.

PMID:
26259721
6.

Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.

Kimura K, Tabo M, Itoh M, Mizoguchi K, Kato A, Suzuki M, Itoh Z, Omura S, Takanashi H.

J Toxicol Sci. 2007 Aug;32(3):217-30.

7.

hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.

DI Veroli GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR.

J Cardiovasc Electrophysiol. 2014 Feb;25(2):197-207. doi: 10.1111/jce.12289. Epub 2013 Oct 7.

PMID:
24118558
8.

Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.

Gillie DJ, Novick SJ, Donovan BT, Payne LA, Townsend C.

J Pharmacol Toxicol Methods. 2013 Jan-Feb;67(1):33-44. doi: 10.1016/j.vascn.2012.10.002. Epub 2012 Oct 26.

PMID:
23103595
9.

Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.

Haraguchi Y, Ohtsuki A, Oka T, Shimizu T.

BMC Pharmacol Toxicol. 2015 Dec 16;16:39. doi: 10.1186/s40360-015-0042-9.

10.

Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.

Beattie KA, Luscombe C, Williams G, Munoz-Muriedas J, Gavaghan DJ, Cui Y, Mirams GR.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):88-96. doi: 10.1016/j.vascn.2013.04.004. Epub 2013 Apr 25.

11.

Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.

Li Z, Dutta S, Sheng J, Tran PN, Wu W, Chang K, Mdluli T, Strauss DG, Colatsky T.

Circ Arrhythm Electrophysiol. 2017 Feb;10(2):e004628. doi: 10.1161/CIRCEP.116.004628. Erratum in: Circ Arrhythm Electrophysiol. 2017 Mar;10 (3):.

PMID:
28202629
12.

Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.

Polak S, Wiśniowska B, Brandys J.

J Appl Toxicol. 2009 Apr;29(3):183-206. doi: 10.1002/jat.1395. Review.

PMID:
18988205
13.

Effects of common antitussive drugs on the hERG potassium channel current.

Deisemann H, Ahrens N, Schlobohm I, Kirchhoff C, Netzer R, Möller C.

J Cardiovasc Pharmacol. 2008 Dec;52(6):494-9. doi: 10.1097/FJC.0b013e31818eec8d.

PMID:
19034038
14.

In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.

Taboureau O, Jørgensen FS.

Comb Chem High Throughput Screen. 2011 Jun 1;14(5):375-87. Review.

PMID:
21470179
15.

2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.

Gordon E, Lozinskaya IM, Lin Z, Semus SF, Blaney FE, Willette RN, Xu X.

Mol Pharmacol. 2008 Mar;73(3):639-51. Epub 2007 Nov 27.

16.
17.

The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.

Diaz GJ, Daniell K, Leitza ST, Martin RL, Su Z, McDermott JS, Cox BF, Gintant GA.

J Pharmacol Toxicol Methods. 2004 Nov-Dec;50(3):187-99.

PMID:
15519905
18.
19.

A history of the role of the hERG channel in cardiac risk assessment.

Rampe D, Brown AM.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):13-22. doi: 10.1016/j.vascn.2013.03.005. Epub 2013 Mar 26.

PMID:
23538024
20.

A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.

Guthrie H, Livingston FS, Gubler U, Garippa R.

J Biomol Screen. 2005 Dec;10(8):832-40. Epub 2005 Oct 18.

PMID:
16234341

Supplemental Content

Support Center